Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
ACNM invites you to submit an original clinical or scientific abstract for the opportunity to present your research during the 2022 SNMMI Mid-Winter and ACNM Annual Meeting in Orlando, Florida.
Abstract submissions from young professionals, including those in training or in practice within 10 years of graduation are strongly encouraged.
With the health and safety of members, volunteers, and attendees in mind, SNMMI made the decision to reschedule the SNMMI Therapeutics Conference, originally scheduled for November 11-13, 2021. The SNMMI Therapeutics Conference will now take place March 10-12, 2022, in New Orleans, LA. Read the full date change announcement.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
A new set of appropriate use criteria is now available to guide referring and imaging physicians in their use of prostate-specific membrane antigen (PSMA) PET imaging agents to detect prostate cancer.
SNMMI’s 10th Annual Patient Education Day drew more than 220 patients, caregivers, and advocates, providing insights into the role of nuclear medicine and molecular imaging in disease diagnosis, staging, and treatment.
Yesterday, the ACMUI Subcommittee on Extravasations reviewed and provided further recommendations on the NRC Staff Preliminary Evaluation of Radiopharmaceutical Extravasation and Medical Event Reporting in a public meeting. In anticipation of the meeting, SNMMI provided public comment.
(Government Relations News)
In September JNM: Editor’s Page: JNM impact factor reaches a new milestone … Discussions with leaders: Caius Radu … State of the Art: Image-Guided HIFU in nuclear medicine … Hot Topics: Cardiac PET and the future … Continuing Education: Pheochromocytoma and paraganglioma … Focus on MI: Current clinical pretargeting … Issues and Controversies: Diversity in nuclear medicine. Featured: Pretargeted immuno-PET in MTC … 68Ga-BMS-986192 for PD-L1 PET … and more.
SNMMI—the leader in radiopharmaceutical therapy education and resources—is excited to announce the launch of a new therapy-focused web portal for members, researchers, the medical community, and patients.
This portal has been created as a repository for all things therapy, providing you with direct access to SNMMI's comprehensive content in one location. We encourage you to bookmark this page for direct access to therapy-related content, including:
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.